Log in

NYSE:DPLO - Diplomat Pharmacy Stock Price, Forecast & News

$3.93
-0.01 (-0.25 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$3.93
Now: $3.93
$3.95
50-Day Range
$3.05
MA: $4.90
$6.19
52-Week Range
$2.43
Now: $3.93
$14.77
Volume5.11 million shs
Average Volume3.14 million shs
Market Capitalization$298.56 million
P/E Ratio19.65
Dividend YieldN/A
Beta0.92
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. Read More…

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.57 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$298.56 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.


Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($2.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $2.15. The business earned $1.30 billion during the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. The business's revenue for the quarter was down 5.3% on a year-over-year basis. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of $-4.91--4.81 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-2.67. The company issued revenue guidance of $$4.9-5.1 billion, compared to the consensus revenue estimate of $$4.87 billion.

What price target have analysts set for DPLO?

13 equities research analysts have issued 1 year price targets for Diplomat Pharmacy's stock. Their forecasts range from $3.00 to $30.00. On average, they anticipate Diplomat Pharmacy's share price to reach $8.88 in the next year. This suggests a possible upside of 125.8% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings and 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

Media coverage about DPLO stock has been trending somewhat negative on Sunday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a news impact score of -1.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Diplomat Pharmacy.

Are investors shorting Diplomat Pharmacy?

Diplomat Pharmacy saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 6,490,000 shares, an increase of 5.4% from the November 14th total of 6,160,000 shares. Based on an average daily trading volume, of 1,640,000 shares, the short-interest ratio is presently 4.0 days. Currently, 11.3% of the shares of the stock are sold short. View Diplomat Pharmacy's Current Options Chain.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Ford Motor (F), CVS Health (CVS), Cannabis Sativa (CBDS), Activision Blizzard (ATVI), Cara Therapeutics (CARA), Celgene (CELG) and Horizon Therapeutics (HZNP).

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stephens Inc. AR (8.59%), State Street Corp (2.56%), Millennium Management LLC (1.90%), Rhenman & Partners Asset Management AB (1.40%), Squarepoint Ops LLC (0.26%) and Rhumbline Advisers (0.24%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which major investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Stephens Inc. AR, Barclays PLC and First Mercantile Trust Co.. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Regina M Benjamin. View Insider Buying and Selling for Diplomat Pharmacy.

Which major investors are buying Diplomat Pharmacy stock?

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Alberta Investment Management Corp, Russell Investments Group Ltd., State Street Corp, State of Alaska Department of Revenue, Rhumbline Advisers and Man Group plc. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $3.93.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $298.56 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  374 (Vote Underperform)
Total Votes:  725
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel